Celebrating developments that defined the cannabis industry in 2022 (and their implications for 2023)
A prevalence of news focuses on a downturn in the availability of capital for the cannabis industry. However, down does not mean out. Investors with an affinity for cannabis continue to see opportunity amid the challenges.
Notable deals include:
- Tilray Brands & Montauk Brewing Co. – On Nov. 7, Tilray Brands announced the acquisition of Montauk Brewing Co., a leading craft brewer in New York. Tilray had previously acquired SweetWater Brewing Co., another leading craft brewer in the U.S. with distribution across more than 40 states; Alpine and Green Flash, iconic Southern California brands; and its leading lifestyle bourbon and spirits brand, Breckenridge Distillery. This deal highlights a strategy we discussed in Q2: Consider other ways to break into a market.
- Cresco Labs & Columbia Care – On March 23, Cresco Labs announced the acquisition of Columbia Care, Inc., in a deal valued at more than $2 billion. Upon closing (expected to occur in Q1 2023), the deal will likely result in the largest multistate operator when measured by pro-forma revenue, Cresco wrote in their release.
- Ascend Wellness & MedMen Enterprises and Verano Holdings & Goodness Growth Holdings – Ascend Wellness entered into an agreement to acquire MedMen Enterprises’ New York operations, and Verano Holdings entered into an agreement to purchase Goodness Growth Holdings. Although neither closed, it was not due to a lack of available capital.
In addition to the mega-deals above, we still see investment capital readily available for operationally efficient and effective companies, and opportunities that project positive cash flows.
And while depressed wholesale and retail prices, limited enterprise values, and other economic challenges persist, investors can seek out solid brands and businesses at a discount from six months ago. As a result, we expect capital to remain available for the right deals in 2023. Investors will focus on deals that improve EBITDA and cash flows and look for opportunities to acquire assets at depressed prices.
On Nov. 8, adult-use cannabis was on the ballot in Arkansas, Maryland, Missouri, North Dakota, and South Dakota. Although the vote counts didn’t break in favor of a clean sweep for legalization, having ballot initiatives in five states should be viewed as positive for the continued erosion of the stigma around cannabis and a step toward further widespread acceptance.
Legalization passed in Maryland and Missouri, opening two additional markets for adult use. The bills in both states included provisions to address decriminalization, expungement, and other social equity initiatives. (More on this later.)
In the next election cycle, we expect the cannabis industry to revisit the ballot initiatives in Arkansas, North Dakota, and South Dakota to rework provisions enabling them to get back on the ballot in 2024 with an improved chance of passing. We also expect continued pushes in medical-only states for adult-use legislation.
2022 saw key developments on this front from a number of sources, including:
- In legalizing adult use, Maryland and Missouri also included provisions to advance critical social justice initiatives for the industry.
- In Maryland, this included:
- The expungement of convictions where the only charge was possession of cannabis
- The right to petition for resentencing of individuals incarcerated for cannabis possession
- Decriminalization of possession for up to 1.5 ounces through June 30, 2023 (the expected date of legalization)
- Allowing the grow of up to two plants beginning July 1, 2023.
- In Missouri, this included:
- The expungement of misdemeanor marijuana offenses
- Decriminalization of possession for up to 3 ounces of cannabis flower or the equivalent in other forms
- Allowing the grow of up to six plants beginning July 1, 2023 (with proper registration)
- Establishing an additional 6% retail tax on nonmedical cannabis sales to support certain community services.
- In Maryland, this included:
- On Oct. 6, President Biden issued a statement on marijuana policy reform focused on three priorities: 1) individuals charged or convicted of prior federal offenses for simple possession of marijuana in violation of a limited set of federal and District of Columbia laws will be issued complete and unconditional pardons, 2) governors are urged to issue identical orders at the state level, and 3) the Secretary of Health and Human Services (HHS) and the Attorney General have been asked to initiate the administrative process to review marijuana’s Schedule 1 classification under the CSA. While the announcement’s legal substance is being debated, it represented a significant shift in federal posturing, which has led to optimism that there will be action on the SAFE Banking Act, and the industry eagerly awaits the review of Schedule 1 classification.
- On Nov. 4, it was announced that Combs Enterprises, owned by Sean “Diddy” Combs, would acquire assets in New York, Illinois, and Massachusetts from Cresco Labs/Columbia Care. According to a release, the deal is expected to create the largest black-owned cannabis company in the world, and affirms Combs’ “commitment to the economic inclusion of underrepresented groups in cannabis.”
For 2023, we expect the cannabis industry to continue focusing on social justice initiatives. Advocates have demonstrated a strong resiliency over a long period, and 2023 bodes no different. An inclusive community is core to the history of cannabis and remains one of the industry’s benchmarks for success.
Celebrating 2022’s successes also provides a chance to double down and drive initiatives even further. Approach 2023 with all that a new year brings: An opportunity to set a new course and implement new plans to grow revenue, provide opportunities for your employees to grow and thrive, and make an impact in your local community.
Benny Herman, CPA, Director
Heather Carter, Technology+, Global Consulting Solutions
ESG, Year in Review, Tax, and more